NUTF2 Antibody

What are the primary applications of NUTF2 antibodies in cancer research?

NUTF2 antibodies serve multiple critical functions in cancer research, including:

• Detection of NUTF2 protein expression in tumor tissues via immunohistochemistry, as demonstrated in Human Protein Atlas studies of HNSC samples

• Quantification of NUTF2 protein levels in cell lines via Western blotting, allowing comparison between cancerous and non-cancerous cells

• Investigation of NUTF2's role in tumor immune microenvironment, particularly its negative correlations with immune cell infiltration

• Validation of NUTF2 knockdown experiments when studying the functional impact of reduced NUTF2 expression on cancer cell behavior

What criteria should researchers consider when selecting a NUTF2 antibody for Western blotting?

When selecting a NUTF2 antibody for Western blotting applications, researchers should evaluate:

• Specificity: Ensure the antibody recognizes human NUTF2 with minimal cross-reactivity to other proteins. Validation using NUTF2 knockdown samples (such as those treated with NUTF2-siRNA) can confirm specificity .

• Sensitivity: The antibody should detect NUTF2 protein at physiologically relevant levels. Research shows NUTF2 is moderately expressed in HNSC samples compared to normal tissues .

• Epitope location: Consider whether the antibody recognizes an epitope that might be masked or altered in experimental conditions.

• Host species: Select an antibody raised in a species that minimizes interference with other antibodies in multiplexed experiments.

• Validation data: Prioritize antibodies with published validation data in similar cancer cell lines (Cal-27, SCC-15, SCC-25) as reported in the literature .

What are the optimal conditions for immunohistochemical detection of NUTF2 in tissue samples?

Based on published research using NUTF2 antibodies for immunohistochemistry:

• Sample preparation: Formalin-fixed, paraffin-embedded (FFPE) tissue sections are standard for NUTF2 detection, as evidenced by Human Protein Atlas immunohistochemistry imaging .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is commonly effective for NUTF2 detection.

• Antibody dilution: Optimal dilution should be determined experimentally, but typically ranges from 1:100 to 1:500 based on antibody concentration.

• Incubation conditions: Overnight incubation at 4°C often yields the best signal-to-noise ratio for nuclear proteins like NUTF2.

• Controls: Include both positive controls (HNSC tissue known to express NUTF2) and negative controls (normal tissue or NUTF2-negative samples) to validate staining specificity .

What troubleshooting strategies are recommended when NUTF2 antibodies show inconsistent results?

When facing inconsistent results with NUTF2 antibodies, consider these research-backed strategies:

• Validation across multiple samples: Compare NUTF2 expression across different cell lines as performed in published studies (NHOK vs. Cal-27, SCC-15, SCC-25) .

• Alternative detection methods: Cross-validate antibody results with mRNA expression analysis using RT-PCR, as demonstrated in studies comparing NUTF2 mRNA and protein levels .

• Optimization of lysis conditions: NUTF2 is a nuclear transport protein; ensure nuclear proteins are adequately extracted using appropriate lysis buffers with nuclear extraction capabilities.

• Antibody lot variation: Test multiple lots or sources of NUTF2 antibodies, especially when replicating published work.

• Sample handling: Ensure consistent sample processing, as variations in fixation time (for IHC) or protein extraction methods can affect NUTF2 detection.

How can NUTF2 antibodies be utilized to study the relationship between NUTF2 expression and immune cell infiltration?

NUTF2 has been demonstrated to negatively correlate with immune cell infiltration in tumors, making this relationship an important area of study . Researchers can utilize NUTF2 antibodies in these advanced applications:

• Multiplex immunofluorescence: Co-stain tumor tissues with NUTF2 antibodies and markers for specific immune cell populations (B cells, CD8+ T cells) to visualize spatial relationships. Research has shown NUTF2 expression is negatively correlated with B cells (R = -0.277; P < 0.0001) and CD8+ T cells (R = -0.317; P < 0.0001) .

• Flow cytometry: Combine NUTF2 antibodies with immune cell markers to quantify correlations between NUTF2 expression levels and immune cell populations in single-cell suspensions.

• Chromatin immunoprecipitation (ChIP): Use NUTF2 antibodies to investigate whether NUTF2 directly regulates genes involved in immune pathways, as GSEA analysis has shown NUTF2 negatively regulates several immune-related pathways, including T cell receptor signaling, B cell receptor signaling, and JAK-STAT signaling .

• Tissue microarray analysis: Apply NUTF2 antibodies to tissue microarrays to study correlations between NUTF2 expression and immune marker expression across large patient cohorts.

What experimental designs best demonstrate the functional impact of NUTF2 on cancer cell behavior?

To effectively study NUTF2's functional impact on cancer behavior, researchers should consider these experimental approaches that incorporate NUTF2 antibodies:

• Knockdown validation: Confirm successful NUTF2 knockdown using NUTF2 antibodies in Western blot analysis after siRNA transfection, as demonstrated in SCC-25 cells .

• Functional assays post-manipulation: After confirming NUTF2 knockdown, measure effects on:

  • Cell proliferation using MTT assays, which have shown decreased proliferation after NUTF2 knockdown

  • Apoptosis using flow cytometry with Annexin V-APC staining, which has demonstrated increased apoptosis rates after NUTF2 knockdown

  • Migration and invasion capabilities using transwell assays

• Rescue experiments: Reintroduce NUTF2 expression in knockdown cells and use NUTF2 antibodies to confirm restoration, then measure whether phenotypic changes are reversed.

• Pathway analysis: Use NUTF2 antibodies alongside antibodies for key signaling molecules to monitor how NUTF2 manipulation affects regulatory pathways identified in GSEA, such as the P53 signaling pathway and the Akt-mTOR signaling pathway .

How can researchers integrate NUTF2 antibody-based data with genomic and transcriptomic analyses?

Integrating NUTF2 protein expression data with genomic and transcriptomic analyses can provide comprehensive insights into NUTF2's role in cancer. Recommended approaches include:

• Multi-omics correlation: Compare NUTF2 protein levels (detected via antibodies) with NUTF2 mRNA expression (from RT-PCR or RNA-seq) to identify post-transcriptional regulation, as performed in studies comparing NUTF2 mRNA expression between tumor and normal tissues .

• Co-expression network analysis: Use NUTF2 antibody data with transcriptomic data to identify proteins co-expressed with NUTF2. Studies using LinkedOmics have identified 6512 genes significantly correlated with NUTF2 in HNSC .

• Pathway enrichment validation: Use NUTF2 antibodies to validate protein-level changes in pathways identified through GSEA or GO analysis. Research has shown NUTF2 is associated with immune-related pathways, including humoral immune response, immunoglobulin-mediated immune response, and B cell-mediated immune response .

• Clinical data integration: Correlate NUTF2 protein expression (via IHC) with genomic alterations and patient outcomes to establish multi-parameter prognostic signatures.

What controls are essential when using NUTF2 antibodies in experimental settings?

Rigorous experimental design requires appropriate controls when using NUTF2 antibodies:

• Positive controls: Include samples known to express NUTF2, such as HNSC cell lines (Cal-27, SCC-15, SCC-25) that have demonstrated high NUTF2 expression .

• Negative controls: Use non-cancerous cell lines (like NHOK) that express lower levels of NUTF2 as comparative controls .

• NUTF2 knockdown samples: Cells transfected with NUTF2-siRNA provide excellent specificity controls for antibody validation .

• Isotype controls: Include matched isotype antibodies to identify non-specific binding.

• Loading controls: For Western blotting, include housekeeping proteins (β-actin, GAPDH) to normalize NUTF2 expression across samples.

• No primary antibody control: Essential for identifying background staining in immunohistochemistry or immunofluorescence applications.

How should researchers address discrepancies between NUTF2 mRNA expression and protein detection?

When researchers encounter discrepancies between NUTF2 mRNA and protein levels, several methodological approaches should be considered:

• Technical validation: Verify results using multiple NUTF2 antibodies targeting different epitopes to rule out antibody-specific artifacts.

• Time-course experiments: Examine whether discrepancies reflect temporal differences between transcription and translation by measuring mRNA and protein at multiple time points.

• Post-translational modification analysis: Investigate whether NUTF2 undergoes modifications that affect antibody detection but not mRNA measurement.

• Protein stability assessment: Determine NUTF2 protein half-life using cycloheximide chase assays and NUTF2 antibody detection to explain potential mRNA-protein discrepancies.

• Subcellular localization: Use fractionation followed by Western blotting with NUTF2 antibodies to determine if the protein localizes to compartments that might affect extraction efficiency.

What are the best practices for quantifying NUTF2 expression in immunohistochemistry samples?

For accurate quantification of NUTF2 expression in immunohistochemistry samples, researchers should follow these evidence-based practices:

How might NUTF2 antibodies be utilized in developing targeted therapies for cancers with high NUTF2 expression?

NUTF2 antibodies could play crucial roles in therapeutic development through these research avenues:

• Antibody-drug conjugates (ADCs): Investigate whether NUTF2 antibodies can deliver cytotoxic payloads specifically to NUTF2-overexpressing cancer cells.

• Mechanistic studies: Use NUTF2 antibodies to elucidate how NUTF2 contributes to immune suppression in the tumor microenvironment, as research has shown NUTF2 negatively regulates immune pathways .

• Candidate screening: Employ NUTF2 antibodies in high-throughput screens to identify compounds that reduce NUTF2 expression or activity.

• Response prediction: Develop NUTF2 antibody-based assays to identify patients likely to benefit from therapies targeting pathways affected by NUTF2, such as JAK-STAT, P53, and Akt-mTOR signaling pathways .

• Combination therapy assessment: Use NUTF2 antibodies to monitor changes in NUTF2 expression during treatment with immune checkpoint inhibitors to develop rational combination strategies.

What potential exists for using NUTF2 antibodies in liquid biopsy applications?

Emerging research suggests NUTF2 antibodies could be valuable in liquid biopsy applications:

• Circulating tumor cell (CTC) detection: Develop protocols using NUTF2 antibodies to identify and isolate CTCs from HNSC patients, particularly since NUTF2 is upregulated in these tumors .

• Exosome characterization: Apply NUTF2 antibodies to detect and quantify NUTF2 protein in tumor-derived exosomes, which may reflect the NUTF2 status of the originating tumor.

• Early response monitoring: Investigate whether changes in NUTF2-positive CTCs correlate with treatment response before radiographic changes are evident.

• Minimal residual disease detection: Develop highly sensitive assays using NUTF2 antibodies to detect microscopic disease after treatment.

• Longitudinal monitoring: Design protocols for serial assessment of NUTF2-expressing cells in patient blood samples to track disease progression and treatment response.

How can NUTF2 antibodies contribute to understanding the role of NUTF2 in immune evasion mechanisms?

Given NUTF2's negative correlation with immune cell infiltration and immune pathways, NUTF2 antibodies can advance understanding of immune evasion through:

• Immune checkpoint correlation studies: Use multiplex immunohistochemistry with NUTF2 antibodies and immune checkpoint markers to investigate spatial relationships, as research has shown NUTF2 correlates with CTLA4 expression in exhausted T cells .

• Single-cell analysis: Apply NUTF2 antibodies in single-cell protein analysis to identify specific immune cell populations affected by NUTF2 expression.

• 3D tumor models: Utilize NUTF2 antibodies in 3D co-culture systems containing immune and cancer cells to study how NUTF2 affects immune cell recruitment and function.

• In vivo immune monitoring: Develop NUTF2 antibody-based imaging approaches to track changes in NUTF2 expression and immune infiltration in animal models during immunotherapy.

• Mechanistic pathway dissection: Use NUTF2 antibodies alongside antibodies for key immune signaling molecules to map how NUTF2 regulates the T cell receptor signaling pathway, B cell receptor signaling pathway, and JAK-STAT signaling pathway identified in GSEA studies .